NASDAQ OMX

Compuware Topaz Removes Go-To-Market Friction by Giving DevOps Fast, Efficient and Secure Access to Enterprise Data

Dela

Advanced Data Visualization, Masking and Conversion  Ensure Agile, Compliant Delivery of Apps and Analytics

  • Enterprises often find themselves unable to tap the full potential business value of their diverse data because DevOps teams can't get all the data they need, when they need it, in the format they require.
     
  • Compuware Topaz for Enterprise Data takes labor, complexity and risk out of the data-to-value pipeline with powerful extraction, masking and visualization for the mainframe and other platforms.
     
  • With Topaz for Enterprise Data, enterprises can empower DevOps staff across skill/experience levels to more quickly, efficiently and securely leverage all available data sources to deliver high-value apps and analytics.

DETROIT, June 28, 2018 (GLOBE NEWSWIRE) -- Compuware today released the new Topaz for Enterprise Data, which provides a powerful combination of data visualization, extract and load, and advanced data masking capabilities. With it, DevOps teams can more quickly, efficiently and securely access and leverage data from the mainframe and other platforms.

Fast, streamlined access to high-value data has become an urgent concern as businesses seek competitive advantages in a digital economy, while fulfilling increasingly stringent compliance requirements. Topaz for Enterprise Data empowers developers, QA staff, operations teams and data scientists at all skill and experience levels to ensure they have immediate, secure access to the data they need, when they need it, in any format required.

Data masking is a top concern, given the importance of protecting personally identifiable information (PII) and complying with regulatory mandates such as GDPR-even during development and testing, especially when outsourcing these functions.

Topaz for Enterprise Data's capabilities are particularly important for enterprises with large, diverse datasets of high business value residing on the mainframe that contain sensitive business or personal information. As senior mainframe professionals retire, large enterprises must transfer responsibility for stewardship of this data to a new generation of DevOps artisans with less hands-on mainframe experience.

Topaz for Enterprise Data empowers these artisans to:

  • Readily understand relationships between data even when they lack direct familiarity with specific data types or applications, to ensure data integrity and resulting code quality.
  • Quickly generate data for testing, training or business analytics purposes that properly and accurately represents actual production data.
  • Ensure that any sensitive business or personal data extracted from production is properly masked for privacy and compliance purposes, while preserving essential data relationships and characteristics.
  • Convert file type as required.

Topaz users can access all these capabilities from within a familiar Eclipse development environment.

"Testing with production-like obfuscated data helps us develop and deliver better quality applications, as well as remain compliant with data privacy requirements," said Lynn Farley, Manager of Data Management at TCF Bank. "Topaz provides our developers with a way to implement data privacy rules to obfuscate multiple data types across platforms and with consistent results."

"Leveraging a modern interface for fast, simple access to data for testing and other purposes is critical to digital agility," said Rich Ptak of IT analyst firm Ptak Associates. "The latest version of Compuware Topaz for Enterprise Data delivers a benefits trifecta to resolve the long-standing challenge of rapidly getting value from the reams of data from disparate sources and formats that are critical to DevOps and continuous improvement."

Today's announcement marks the 15th consecutive quarter that Compuware has delivered essential innovation to help large enterprises master Agile and DevOps tasks on a mainstreamed mainframe, so they can best leverage the platform's unmatched performance, scalability, reliability, efficiency and security.

"The wealth of data that should give large enterprises a major competitive advantage in the digital economy often instead becomes a hindrance due to the complexity of sourcing across platforms, databases and formats," said Chris O'Malley, CEO of Compuware. "With Topaz for Enterprise Data, Compuware is removing these hindrances-so there's far less friction between enterprise data and business wins."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Frank Cioffi, The Medialink Group, frankc@medialinkgroup.com, (415) 893-1570
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum